Kura Oncology, Inc.

NASDAQ:KURA

Biotechnology

Healthcare
$7.34 +0.73%

+$0.07 today

Market cap
$674.39M
Beta
0.36
P/E (TTM)
-2.9
EPS (TTM)
-$3.32
52W Low $5.45High $12.49

Volume 2.46M

Average 1.66M

KURA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Kura Oncology, Inc.NASDAQ: KURA

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $8.42M rose 7.3% year over year, behind the +13.4% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 25.9% from the prior quarter. Over 3 fiscal years it compounded at +12.1% a year.

Context

  • Stock-based compensation amounted to 55.0% of revenue in FY2025, down 7.9 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +7.3% toward the trailing-twelve-month pace of +13.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.42M-25.9% QoQ
Last fiscal yearDec 2025
$37.11M+9.5% YoY
LTMMar 2026
$37.68M+13.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.3%——
1 year+9.5%——
3-year CAGR+12.1%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
37.11M USD
Year-over-year change
+9.5%
4-year CAGR
+12.0%

Stock-Based Compensation vs competitors

How KURA compares with its peers on the latest reported figures

  • KURA's LTM Mar 2026 stock-based compensation of $37.68M is the 3rd largest of the 11 companies compared; the peer median is $15.42M.
  • Its year-over-year change of +13.4% is the 8th highest of 11, against a peer median of +20.5%.
  • Stock-based compensation amounts to 52.6% of revenue for KURA, versus a peer median of 12.6%.
KURA Competitors Peer median
Stock-Based Compensation for KURA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$49.18M +10.5%+43.7%22.6%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$40.66M +8.7%+10.5%5.8%
KURAKura Oncology, Inc.LTM Mar 2026$37.68M +13.4%+12.1%52.6%
TYRATyra Biosciences, Inc.LTM Mar 2026$29.43M +17.2%+38.3%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$25.38M +66.4%——
HCMHUTCHMED (China) LimitedLTM Jun 2025$17.99M -47.3%-20.6%3.0%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$12.84M +21.4%+0.9%4.3%
VSTMVerastem, Inc.LTM Mar 2026$9.66M +26.4%+15.9%19.5%
CRDFCardiff Oncology, Inc.LTM Mar 2026$5.99M +19.7%+10.2%1140.6%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$4.19M +122.7%+4.3%—
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 2026$3.82M +1696.3%——
Peer median (excluding KURA) $15.42M+20.5%+10.3%12.6%

Competitors are the stored peer set for KURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(130.47M)(135.84M)(152.63M)(173.98M)(278.67M)
Depreciation & Amortization558K759K849K848K(7.46M)
Deferred Income Tax4.6M0000
Stock-Based Compensation23.58M26.32M28.08M33.9M37.11M
Change in Working Capital(3.22M)(2.98M)7.82M286.17M184.44M
Accounts Receivables0000(6.74M)
Inventory0000(413K)
Accounts Payables(2.52M)(802K)10.33M15.2M4.5M
Other Working Capital(706K)(2.18M)(2.51M)270.97M187.1M
Other Non-Cash Items399K1.68M(8.94M)(12.62M)515K
Operating Cash Flow(104.55M)(110.06M)(124.82M)134.32M(64.06M)
Capital Expenditures(1.15M)(626K)(168K)(472K)(6.64M)
Acquisitions (Net)125.69K(33.25K)000
Purchases of Investments(445.66M)(270.66M)(409.82M)(659.05M)(761.59M)
Sales of Investments319.97M303.91M425.55M557.93M755.13M
Other Investing Activities(125.69K)33.25K000
Investing Cash Flow(126.84M)32.63M15.56M(101.59M)(13.1M)
Debt Repayment(7.25M)10M000
Common Stock Issued4.43M24.72M93.58M145.81M1.79M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(611K)3.84M1.21M8.6M0
Financing Cash Flow(3.44M)38.57M94.78M154.42M1.79M
Effect of Forex Changes00000
Net Change in Cash(234.82M)(38.87M)(14.48M)187.14M(75.36M)
Free Cash Flow(105.7M)(110.69M)(124.99M)133.85M(70.7M)

Kura Oncology, Inc.

NASDAQ:KURA

Intrinsic Alpha fair value

Locked

Current Price

$7.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.